DeCure's autonomous AMR AI scientist is researching a drug-repurposing hypothesis for HIV infection — screening already-approved drugs against its 46-gene Open Targets disease module to publish open-access research. Research is fast; the path to publication is funded in milestone stages.
Disease moduleHIV infection maps to a 46-gene Open Targets module — the target space DeCure's AI scientist screens approved drugs against.
DeCure.ai methodSignature reversal (LINCS) plus network proximity (STRING) rank already-approved drugs likely to perturb this module — the same engine that produces DeCure.ai's repurposing hypotheses.
Repurposing thesisScreening approved medicines against this disease module, then publishing the evidence for the strongest candidate. Known pharmacology and human exposure data make the first question sharper — they do not establish safety or efficacy in a new indication.
Research record
01
ResearchComing soon
Candidate research + dossier — target rationale, drug-repurposing thesis and evidence pack.proof: Published dossier + on-chain hash
02
ValidationComing soon
In-vitro biological validation at a contract research org (CRO).proof: CRO contract + in-vitro report
03
Peer review & paperComing soon
Peer-reviewed paper published open-access (preprint + journal).proof: DOI + open-access link + on-chain hash
Current lead
No approved-drug candidate for hiv infection is corroborated in the literature DeepSearch retrieved. Some conditions are managed with non-pharmacological care — a device, surgery or physical therapy — rather than a medicine; that may be the case here, or the literature we found may simply be too sparse yet to support a drug-repurposing angle.
Molecular view
cytochrome P450 family 3 subfamily A member 4 (CYP3A4) — CYP3A4 is one of the genes genetically linked to this disease in Open Targets — shown as context, not as a drug target we're pursuing: no approved-drug candidate for this disease is yet corroborated in the literature we found.
Loading structure…
helix sheet hemdrag to rotate · scroll to zoom
RCSB Protein Data Bank · entry 5VCC · 1.7 Å · ligand PROTOPORPHYRIN IX CONTAINING FE (HEM). Experimental structure, not a prediction.
What the evidence adds up to
A 1999 letter described a patient, referred to as the Berlin patient, who was treated soon after acute HIV infection with a combination of hydroxyurea (400 mg three times daily) and didanosine, before complete seroconversion on Western blotting. The authors noted that eradication of HIV is difficult because a reservoir of replication-competent virus persists in resting CD4 T lymphocytes even after years of highly active antiretroviral treatment, and suggested that a more realistic goal than lifelong therapy might be to control HIV as occurs in long-term nonprogressors.
A 2013 review provided a general overview of immune responses and cell signalling during chronic HIV infection, describing the immune system's components and how they interact at the molecular level to fight HIV. It did not report any new experimental data or clinical results.
A 2024 bioinformatics study analysed 100 candidate genes potentially involved in HIV attachment to cells, comparing them to background genes (CCR5, CXCR4, CCR2, CD4) known to be reliably linked to HIV attachment. Using a scoring system based on expression data, localisation, and involvement in biological pathways and processes, the study identified 55 candidate genes as significant. These were classified into functional groups including chemokine co-receptors and their ligands, genes associated with G-proteins, and a group without a common functional family. The authors concluded that the identified correlations highlight the need for further investigation of these gene interactions in HIV pathogenesis.
What is still missing is a clinical trial testing any of the candidate genes identified in the 2024 bioinformatics study as therapeutic targets, and any evidence that the hydroxyurea and didanosine regimen used in the 1999 Berlin patient has been replicated in a controlled study. No data on survival, response rates, or sample sizes beyond a single patient were provided in any of the abstracts.
Evidence
Retrieved by DeepSearch across 234,678,978 indexed works and resolved on OpenAlex — ranked by citations, including the results that did not work.
New England Journal of Medicine · 1999 · 328 citations · open access
Control of HIV despite the Discontinuation of Antiretroviral Therapy
AbstractTo the Editor: Eradication of the human immunodeficiency virus (HIV) is a difficult goal to achieve, because a reservoir of replication-competent HIV is established in resting CD4 T lymphocytes soon after infection and persists after years of highly active antiretroviral treatment.1 A more realistic alternative to lifelong cumbersome, toxic, and expensive treatments is to control HIV, as occurs in patients with long-term nonprogression of the disease. A patient, who has become known as “the Berlin patient,” was treated soon after acute HIV infection, before complete seroconversion on Western blotting, with a combination of hydroxyurea (400 mg three times daily),2 didanosine . . .
Immune Responses and Cell Signaling During Chronic HIV Infection
AbstractThe immune response can be defined by the reaction of the immune system to a particular antigen to which it is exposed. In order to understand immune responses against an infectious agent such as human immunodeficiency virus (HIV) and their regulation during the course of chronic HIV infection, we will provide a brief overview of HIV and its proteins and attempt to shed light on this disease process. We will also review the immune system, its components and describe how these components interact at the molecular levels to fight an invading pathogen such as HIV.
Russian Journal of Infection and Immunity · 2024 · 3 citations · open access
Bioinformatically analyzed relationships between specific human genes associated with HIV attachment
AbstractIntroduction. Assessing interaction between the human immunodeficiency virus (HIV) and human factors is crucial for understanding the disease pathogenesis. HIV triggers an immune response that involves numerous cellular and molecular processes related to inflammation, cell migration, and disrupted tissue barrier functions. Such reactions build up a cascade in which chemokines and cognate co-receptors, as well as other molecules regulating the immune response, play a key role. However, the interaction between HIV and the human organism cannot be reduced to a simple mechanism because it represents a multilayered system where crucial molecules and events may be unknown or require further study. Objective: to assess a significance of candidate genes potentially involved in the pathogenesis of HIV infection during the phase of viral attachment to cell, based on assessing gene expression, localization, and involvement in biological pathways and processes. Materials and methods. The study compared the characteristics of the 100 most promising candidate genes (CG) according to the HumanNet web resource with background genes (CCR5, CXCR4, CCR2, CD4), known to be reliably linked to HIV attachment. Expression data, localization, and involvement in various cellular pathways and processes for the candidate and background genes were analyzed. A scoring system was developed to assess the significance of each gene in the context of its role in immune and inflammatory responses. Results. A total of 100 candidate genes were analyzed. Using the developed scoring system, a number of genes were identified as significant based on the analyzed parameter: 17 candidates — significant by expression profile; 7 — by localization; 17 — by involvement in biological pathways; and 25 — by involvement in biological processes. The final ranking revealed 55 candidate genes. The identified candidate genes were classified into the following functional groups: chemokine co-receptors and their ligands; genes and proteins associated with G-proteins; and a group for which a common functional role or family could not be established. Conclusions. The identified correlations between the candidate genes and background genes highlight the need to further investigate CG interactions in HIV pathogenesis allowing for a more detailed assessment of the contribution of both individual genes and entire systems, which, in the future, will expand our understanding of the molecular mechanisms behind HIV infection and, hypothetically, accelerate the discovery of new (or the expansion of existing) therapeutic models.
Disease module: DeepOracle (Open Targets). Structures: RDKit from PubChem SMILES. Literature: retrieved by DeepSearch across 234,678,978 indexed works (targeted per-candidate search), resolved on OpenAlex.
DeCure is a research and publication project, not medical advice and not a treatment. "DeCure for X" describes a research goal, not a claim that a cure exists. Backing a cure is a contribution to fund the research — it is not an investment, and confers no yield, royalty, equity or IP ownership. Papers are published open-access by the DeCure.ai DAO.
